Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris Sells 10,309 Shares

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 10,309 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $240,508.97. Following the completion of the sale, the director now owns 59,792 shares in the company, valued at $1,394,947.36. This represents a 14.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Privia Health Group Stock Up 1.8 %

PRVA stock opened at $23.32 on Friday. Privia Health Group, Inc. has a 52 week low of $15.92 and a 52 week high of $26.04. The business has a 50-day simple moving average of $23.50 and a 200 day simple moving average of $22.07. The company has a market cap of $2.83 billion, a PE ratio of 233.22, a price-to-earnings-growth ratio of 3.47 and a beta of 0.88.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Truist Financial increased their price target on Privia Health Group from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, April 10th. Canaccord Genuity Group lifted their target price on shares of Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Piper Sandler increased their price target on shares of Privia Health Group from $25.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Robert W. Baird upped their target price on Privia Health Group from $24.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday, April 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $30.00 price target on shares of Privia Health Group in a report on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $27.38.

Hedge Funds Weigh In On Privia Health Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. Durable Capital Partners LP increased its stake in Privia Health Group by 3.4% in the fourth quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company’s stock valued at $224,587,000 after acquiring an additional 378,255 shares during the last quarter. Riverbridge Partners LLC raised its holdings in shares of Privia Health Group by 19.7% during the 4th quarter. Riverbridge Partners LLC now owns 5,824,458 shares of the company’s stock worth $113,868,000 after buying an additional 958,418 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of Privia Health Group by 19.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,488,979 shares of the company’s stock worth $29,110,000 after buying an additional 246,393 shares during the last quarter. Loomis Sayles & Co. L P boosted its stake in Privia Health Group by 55.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,418,234 shares of the company’s stock valued at $27,727,000 after buying an additional 503,002 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Privia Health Group by 10.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,416,235 shares of the company’s stock valued at $27,687,000 after acquiring an additional 138,747 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.